TPI 287 in Breast Cancer Metastatic to the Brain
A Phase 2 Open-Label Study of TPI 287 in Patients With Breast Cancer Metastatic to the Brain
Sponsor: Cortice Biosciences, Inc.
This PHASE2 trial investigates Breast Cancer and is currently completed. Cortice Biosciences, Inc. leads this study, which shows 9 recorded versions since 2011 — indicating limited longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.
Status Flow
Change History
9 versions recorded-
Sep 2024 — Present [monthly]
Completed PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE2
-
Jan 2021 — Jul 2024 [monthly]
Completed PHASE2
-
Oct 2018 — Jan 2021 [monthly]
Completed PHASE2
-
Aug 2018 — Oct 2018 [monthly]
Completed PHASE2
▶ Show 4 earlier versions
-
Jun 2018 — Aug 2018 [monthly]
Completed PHASE2
-
May 2017 — Jun 2018 [monthly]
Completed PHASE2
Status: Active Not Recruiting → Completed
-
Feb 2017 — May 2017 [monthly]
Active Not Recruiting PHASE2
-
Jan 2017 — Feb 2017 [monthly]
Active Not Recruiting PHASE2
First recorded
Aug 2011
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Cortice Biosciences, Inc.
- M.D. Anderson Cancer Center
For direct contact, visit the study record on ClinicalTrials.gov .